Clinical phenotype and management of sound-induced pain: Insights from adults with pain hyperacusis

Kelly N. Jahn^{a,b*}, Sean Takamoto Kashiwagura^{a,b}, Muhammad Saad Yousuf^{c*}

^a Department of Speech, Language, and Hearing, The University of Texas at Dallas, Richardson, TX, USA

^b Callier Center for Communication Disorders, The University of Texas at Dallas, Dallas, TX, USA

^c Department of Neuroscience and Center for Advanced Pain Studies, The University of Texas at Dallas, Richardson, TX, USA

* Corresponding authors

ABSTRACT: Pain hyperacusis, also known as noxacusis, causes physical pain in response to everyday sounds that do not bother most people. How sound causes excruciating pain that can last for weeks or months in otherwise healthy individuals is not well understood, resulting in a lack of effective treatments. To address this gap, we identified the most salient physical and psychosocial consequences of debilitating sound-induced pain and reviewed the interventions that sufferers have sought for pain relief to gain insights into the underlying mechanisms of the condition. Adults (n = 32) with pain hyperacusis attended a virtual focus group to describe their sound-induced pain. They completed three surveys to identify common symptoms and themes that defined their condition and to describe their use of pharmaceutical and non-pharmaceutical therapies for pain relief. All participants endorsed negative effects of pain hyperacusis on psychosocial and physical function. Most reported sound-induced burning (80.77%), stabbing (76.92%), throbbing (73.08%), and pinching (53.85%) that occurs either in the ear or elsewhere in the body (i.e., referred pain). Participants reported using numerous pharmaceutical and nonpharmaceutical interventions to alleviate their pain with varying degrees of pain relief. Benzodiazepines and nerve blockers emerged as the most effective analgesic options while nonpharmaceutical therapies were largely ineffective. Symptoms of pain hyperacusis and therapeutic approaches are largely consistent with peripheral mechanistic theories of pain hyperacusis (e.g., trigeminal nerve involvement). An interdisciplinary approach to clinical studies and the development of animal models is needed to identify, validate, and treat the pathological mechanisms of pain hyperacusis.

1 INTRODUCTION

2 Approximately 15% of adults [6] and 17% of children [15] suffer from hyperacusis, a 3 disorder characterized by an inability to tolerate ordinary sounds that do not bother most people 4 [19]. Some individuals perceive everyday sounds to be excessively loud (i.e., loudness 5 hyperacusis), whereas others experience physical pain in response to sounds (i.e., pain 6 hyperacusis or noxacusis) [19]. The relative prevalence of these two hyperacusis subtypes is 7 unknown, but a recent survey demonstrated that 62.5% of adults with hyperacusis experience 8 some level of sound-induced physical pain [21]. Individuals with pain hyperacusis often present 9 with a relatively severe clinical phenotype, wherein they report frequent "setbacks" (i.e., 10 symptom exacerbations in response to a trigger sound) and reduced benefit from behavioral 11 interventions (e.g., sound therapy) [21]. Despite the severity of pain hyperacusis, healthcare 12 professionals have limited tools to diagnose, monitor, and treat the condition [2] and they do not 13 widely recognize the pain hyperacusis phenotype [7].

14 A primary reason for the lack effective clinical tools for pain hyperacusis is that the 15 underlying mechanisms of sound-induced pain remain elusive [6]. Existing theories of the neural 16 underpinnings of pain hyperacusis implicate structures ranging from the middle ear to the inner 17 ear to the central auditory pathway (Figure 1). Middle ear models of sound-induced pain broadly 18 suggest that overload, damage, or myoclonus of the tensor tympani muscle can irritate the 19 trigeminal nerve and cause pain in or near the ear [12,20]. Others have shown that Type-II 20 cochlear afferents share similar morphological and neurochemical properties with nociceptive 21 somatic C fibers and may transmit damage-evoked pain signals from the inner ear to the central 22 nervous system (CNS) [4,10,22]. Finally, a large body of basic science literature demonstrates 23 that damage to the peripheral auditory system leads to a cascade of downstream changes that

elicit abnormally elevated neural activity along the central auditory pathway and which may leadto perceptual hypersensitivity in rodents [1].

26 Existing conceptual frameworks of the biological underpinnings of pain hyperacusis lack 27 empirical evidence from humans, relying largely on theory [12,20] or animal models [1,22]. 28 Consequently, pain hyperacusis remains poorly treated and responds inadequately to existing 29 therapies, highlighting the urgent need for more effective solutions. We surmise that the 30 mechanisms of pain hyperacusis will continue to remain elusive without a thorough 31 understanding of how the condition manifests physically and the types of interventions that can 32 alleviate sound-induced pain. Here, we used a participatory research method to generate a 33 conceptual framework for understanding the most salient symptoms of pain hyperacusis from the 34 perspective of individuals who suffer from the condition. We also identified pharmaceutical and 35 non-pharmaceutical interventions that the participants have tried and the perceived efficacy of 36 each. We aimed to characterize the specific physical and psychosocial consequences of sound-37 related pain and to generate a preliminary dataset to identify interventions that may provide pain 38 relief. These data will be used to develop targeted clinical trials aimed at identifying effective 39 treatments for pain hyperacusis which, in turn, will aid in uncovering the underlying mechanisms 40 of this condition in humans.

41

42 METHODS

43

44 *Participants*

This study was approved by the Institutional Review Board of The University of Texas at
Dallas (IRB-23-200) and all participants provided written informed consent to participate. A

47 snowball sampling technique was used to recruit prospective participants, and recruitment flyers 48 were posted online on our laboratory website, social media (Facebook, Instagram, and 49 Twitter/X), and a research recruitment registry (ResearchMatch.org). A total of 32 fluent English-50 speaking adults (age 19-65 years, mean age = 37 years, 11 female) who self-reported that they 51 experience physical pain when they hear sounds participated. All participants had experienced 52 pain hyperacusis for at least one year (range 1 to 27 years). Other self-reported co-morbid 53 audiovestibular, neurological, mental health, and chronic pain conditions are listed in **Table 1**.

54

55 *Procedures*

56 We first used a modified concept mapping approach to identify the key symptoms and 57 experiences associated with sound-induced pain [3,17]. Concept mapping is a participatory 58 research method that combines qualitative and quantitative techniques to develop a conceptual 59 framework for how stakeholders (here, adults with pain hyperacusis) experience a particular 60 phenomenon. The concept mapping portion of the study consisted of three primary stages 61 (brainstorming, rating, and sorting), outlined in the following sections. We also disseminated a survey to comprehensively characterize the pharmaceutical and non-pharmaceutical 62 63 interventions that these participants have tried, and the perceived effectiveness of each 64 intervention.

65

66 Concept Mapping Stage 1: Brainstorming (Virtual Focus Group)

67 The purpose of the concept mapping brainstorming stage is to generate a set of statements 68 that represent the conceptual domain for the topic of interest from the perspective of stakeholders 69 themselves [18]. In the present study, participants (n = 26) joined a 60-minute virtual focus group

held on the Microsoft Teams platform. During the session, the participants were asked to
generate as many statements as possible describing: 1) Characteristics of their sound-related
pain, and 2) Symptoms related to sound sensitivity or hyperacusis.

73 Some participants with severe pain hyperacusis were unable to speak or listen to others' 74 voices, so we offered multiple accommodations to ensure that all participants had equal 75 opportunity to respond to the focus prompts. Participants were allowed join the focus group with 76 or without audio and we provided instructions for utilizing automatically generated closed 77 captions. Additionally, participants could elect to respond to the focus prompts via either spoken 78 word or text. The Microsoft Teams meeting was recorded so that verbal responses could be 79 transcribed after the session. To facilitate text-based communication, participants received a 80 private link to a Google Docs document to respond to the focus prompts in real time. They were 81 also allowed to enter comments or questions into the Microsoft Teams chat box. All participants 82 had access to the focus prompts during the entire session and were able to freely respond and 83 view other participant responses. Participants were allowed to share additional information about 84 their experiences via email after the focus group.

After the session, the research team reviewed all written and verbal responses. We eliminated redundant ideas and condensed the responses into a set of 92 statements that encompassed all unique ideas generated during the focus group (**Table 2**). The resulting set of 92 statements served as the content for the next two stages of the study (i.e., rating and sorting tasks).

92 The purpose of the concept mapping rating stage is to allow participants to rate each 93 statement on a dimension of interest to indicate how much the statement embodies their overall 94 experience with the topic [18]. It is possible that some symptoms and consequences of pain 95 hyperacusis are more common than others. Thus, the goal of the rating task in this study was to 96 determine how common it is for an individual with pain hyperacusis to experience each of the 97 symptoms discussed during the focus group. Participants (n = 26) completed an online survey 98 where they viewed all 92 statements and rated how well each statement applied to their own 99 personal experience with pain hyperacusis. Twenty of these participants had attended the focus 100 group, and 6 were new participants who were unable to attend the focus group. They received a 101 private link to a Qualtrics survey, where each statement was displayed in random sequence 102 alongside a 5-point Likert scale. Most statements (78 out of 92) were rated on a scale with 103 response choices of Never, Sometimes, About Half the Time, Most of the Time, and Always. For 104 clarity, a scale with response choices of Strongly Disagree, Somewhat Disagree, Neither Agree 105 nor Disagree, Somewhat Agree, and Strongly Agree was used for 14 statements [Statement 106 numbers S79-S92; see Table 2] due to their linguistic structure.

107

108 Concept Mapping Stage 3: Sorting the Statements

109 The purpose of the concept mapping sorting stage is to identify interrelationships, or 110 themes, amongst the statements [18]. Individuals that completed the rating task were invited to 111 complete a follow-up activity where they viewed all 92 statements for a second time and sorted 112 the statements into categories based on perceived similarities between the statements. The goal 113 of this task was to assist the research team in identifying categories and themes within the data. 114 Participants received a private link to view and sort the statements within OptimalSort – Card

115 Sorting software (Optimal Workshop Ltd.). Participants were instructed to organize the 116 statements into categories in a way that made sense to them based on thematic similarity. They 117 were instructed to sort each statement into a category, regardless of whether the statement 118 applied to their own personal situation, and that they should not create a "does not apply" 119 category. They were told that a statement could be placed in its own category if it was unrelated 120 to other statements, but they should not create "miscellaneous" or "other" categories. Once a 121 participant sorted all statements into categories, they were prompted to name each category that 122 they created. Twenty-five participants initiated the sorting task. Of those 25 participants, four did 123 not sort all 92 statements into a category and six created a "does not apply" category despite 124 instructions to the contrary. The categories generated by the remaining 15 participants were used 125 in subsequent analyses. Note that 15 is a sufficient sample size for the sorting stage of a concept 126 mapping study, as the goal of this task is primarily to guide the experimenters in identifying 127 conceptual themes in the data [18].

128

129 Intervention Survey

130 After the concept mapping portion of the study, we disseminated a survey to determine 131 whether these participants had tried any pharmaceutical or non-pharmaceutical interventions for 132 pain hyperacusis and, if so, whether those treatments were effective at alleviating their sound-133 induced pain. Twenty-four participants completed the follow-up survey. Participants were asked 134 to indicate whether they have ever used opioid, non-opioid prescription or over-the-counter 135 medications, oral or inhaled cannabinoids (marijuana, THC, and/or CBD), Botox injections, or 136 non-pharmaceutical interventions for pain hyperacusis. If they answered "yes" to any of those 137 questions, they viewed a list of relevant medications or interventions and selected all that they

had tried. Each question had an open-ended "Other" option for choices that were not listed. For
each intervention selected, participants were asked to indicate whether it helped, hurt, or had no
effect on their pain hyperacusis using a 5-point Likert scale with the following options: *Excellent effect (>90% pain relief), Modest effect (75% pain relief), Somewhat effective (50% pain relief), No effect (0% pain relief), Made my noxacusis worse.* For each non-pharmaceutical intervention,
participants were asked to describe who administered the treatment (e.g., self-administered,
licensed professional).

145

146 Data analysis

147 Data were analyzed in R (Version 4.2.2) and MATLAB (MathWorks, Inc., Natick, MA). 148 Responses from the sorting task were analyzed using multidimensional scaling and hierarchical cluster analyses. A symmetric 92 X 92 similarity matrix was generated for each participant that 149 150 indicated which statements they grouped together during the sorting task. The individual 151 similarity matrices were added together to produce a total similarity matrix, which indicated how 152 many participants in the entire sample grouped the same two statements together. The total 153 similarity matrix was transformed into a matrix of Euclidean distances using the MATLAB pdist 154 function. Statements that were grouped together more frequently by participants are closer 155 together in Euclidean space (i.e., they have a smaller Euclidean distance) than statements that 156 were grouped together less frequently.

Using the MATLAB *cluster* function, the Euclidean distances were submitted to a hierarchical cluster analysis to group individual statements into clusters of statements that reflected similar concepts [17]. The maximum number of clusters was first selected based on the average number of categories that the participants created (Mean = 12 categories, Range = 3-26

161 categories). The research team reviewed the statements within the 12 clusters and discussed 162 whether it was appropriate to increase or decrease the number of clusters to better categorize the 163 subjective data [5]. After examining five possible cluster solutions, two of the authors (KNJ and 164 STK) reached a consensus that 17 clusters provided a reasonable level of specificity based on the 165 subjective content matter. The clusters represented 17 different concepts or themes within the 166 data. The authors named each of the 17 clusters with guidance from the category labels that the 167 participants generated during data collection (**Table 2**).

168 Participants' rating scores were used to identify the relative importance of each cluster 169 and each statement to the pain hyperacusis experience. This was determined by performing two 170 separate analyses. Point values were assigned to the Likert scale response choices as follows: 1 =171 Never, 2 = Sometimes, 3 = About Half the Time, 4 = Most of the Time, and 5 = Always and 1 = AlwaysStrongly Disagree, 2 = Somewhat Disagree, 3 = Neither Agree nor Disagree, 4 = Somewhat 172 173 Agree, and 5 = Strongly Agree. To identify the most salient clusters, the rating scores were 174 averaged across all participants and across all statements within each cluster. Clusters with 175 higher average ratings were interpreted as more common to the lived experience of pain 176 hyperacusis than clusters with lower average ratings.

For individual statements, we also calculated the percentage of participants that provided each Likert scale response. Any response other than "Never" or "Strongly Disagree" was considered an endorsement of the corresponding statement (i.e., the person experiences the symptom at least sometimes or agrees with the statement at least some of the time). Statements that were endorsed by a higher percentage of participants were interpreted as more common to the lived experience of pain hyperacusis than statements that were endorsed by a lower percentage of participants.

184

185 RESULTS

186 Concept Mapping

187 Hierarchical cluster analyses revealed a 17-cluster solution that described the most salient 188 characteristics and consequences of sound-induced pain generated during the focus group (Table 189 **2**). The 17 clusters arranged in order from highest-to-lowest average rating are: *Lack of Empathy* 190 or Support from Others; Isolation and Reduced Physical Activity; Symptom Setbacks; Mental 191 Health Consequences; Pain Triggers, Severity, and Time course; Control and Avoidance 192 Behaviors; Pain Laterality; Emotional Reactions to Sound; Symptom Onset; Neuropathic Pain; 193 Fluctuating Severity; Otologic Symptoms (Non-pain); Interference with Essential Functions; 194 Other Sensory Sensitivities; Irritation/Inflammation; Referred Pain; and Head Sensations. The 195 average ratings for each cluster ranged from 1.66 for *Head Sensations* (least common across all 196 participants) to 4.21 for Lack of Empathy or Support from Others (most common across all 197 participants). Table 2 lists the 17 clusters, the average rating for each cluster, the individual 198 statements within each cluster, the average rating for each statement, and the percentage of 199 participants who endorsed each statement at least sometimes.

Figure 2 shows the percentage of participants who endorsed each statement related to the quality and location of their pain (i.e., clusters describing *Neuropathic Pain* and *Referred Pain*) along with a visual schematic of those data. The pain was most often described as a burning (80.77%), stabbing (76.92%), throbbing (73.08%), or pinching (53.85%) sensation. Although 92.31% of participants reported that the pain can occur in or near their ears, less than half of participants (42.31%) indicated that this was "Always" the case. Many participants reported referred pain in addition to pain in or near the ears, including pain in the face (73.08%), head

(side – 57.69%, back – 42.31%, front – 30.77%), throat (34.62%), neck (53.85%), and elsewhere
in the body (46.15%; i.e., outside the head and neck region). More than half of participants
indicated that their sound-related pain can change locations (65.38%) and that the quality and
severity of the sound-related pain can fluctuate (**Table 2**, *Fluctuating Severity* cluster).

211 In addition to the physical characteristics of the pain itself, participants consistently 212 reported experiencing setbacks after sound exposure (Table 2, Symptom Setback cluster) and 213 described common triggers and factors that influence the severity and temporal characteristics of 214 the pain (Table 2, Pain Triggers, Severity, and Time Course cluster). We also note that although 215 80.77% of the participants endorsed bilateral sound-related pain, many reported unilateral pain 216 (46.15%) or symptoms that are asymmetric in severity (84.62%) (**Table 2**, *Pain Laterality* 217 cluster). A smaller, but noteworthy, percentage of participants endorsed symptoms such as 218 inflammation (61.54%), itchiness (73.08%), or redness (30.77%) near the site of their sound-219 related pain and other head-related sensations such as fullness/pressure (61.54%), migraines 220 (30.77%), dizziness (30.77%), or nausea (26.92%) associated with sound exposure (**Table 2**).

As hyperacusis is often considered to be a disorder of the ear, we were interested in understanding what other otologic and sensory symptoms these individuals may experience (Figure 3; Table 2). Almost all participants (96.15%) experience tinnitus (perception of phantom sounds), and their tinnitus is often reactive (88.46%) (i.e., exacerbated by the presence of external sounds) (Figure 3A). Most participants reported additional, non-pain sensations in the ear such as fullness or pressure (80.77%), fluttering (80.77%), pulsing (65.38%), and vibrations (57.69%) and other sensory sensitivities (53.85%) (Figure 3; Table 1).

In addition to describing physical and sensory symptoms, participants often discussed the emotional and psychosocial consequences of pain hyperacusis. Clusters related to emotional and

psychosocial symptoms were highly rated across participants, suggesting that these experiences may be more consistent than the physical manifestation of the pain itself. **Figure 4** shows the percentage of participants who endorsed a lack of empathy or support from others, which was the highest-rated cluster. All participants reported that individuals within their social network do not understand their hyperacusis symptoms, with 100% endorsing this concept for family and friends, and 96.15% indicating that medical and healthcare professionals do not understand their symptoms (**Figure 4**; **Table 2**).

237 Figure 5 shows the percentage of participants who endorsed each statement within the 238 top two emotional and psychosocial clusters (i.e., Isolation and Reduced Physical Activity and 239 Mental Health Consequences). Every participant indicated that their lifestyle has changed 240 significantly since the onset of their hyperacusis, with the vast majority endorsing all statements 241 related to isolation and reduced physical activity (range 84.62% to 100%) and mental health 242 concerns (range 88.46% to 96.15%) (Figure 5; Table 2). To manage their symptoms, most of the 243 participants use control and avoidance techniques such as wearing hearing protection devices 244 (96.15%) and planning their lifestyle to avoid sound exposure (100%) (**Table 2**).

245

246 Intervention Survey

Overall, participants unanimously reported pain sensations (**Figure 2**; e.g., burning, stabbing, pinching) that are consistent with possible damage, disease, or dysfunction of one or more peripheral nerves. We created and disseminated a survey to identify potential treatment response patterns that could shed light on the underlying mechanisms of pain hyperacusis in humans. Participants reported that they have tried a variety of treatments to alleviate soundinduced pain, with most participants (87.50%, n = 21) having tried both pharmaceutical and non-

pharmaceutical therapies (**Figure 6, Table 3**). The average participant reported using 4.88 different therapies (range 0 to 12), with 58.33% (n = 14) trying multiple pharmaceuticals and 66.67% (n = 16) trying multiple non-pharmaceutical therapies (**Figure 6**).

256 Those who use pharmaceuticals reported the following drugs, in descending order of 257 frequency: oral or inhaled cannabinoids (e.g., marijuana, THC, and/or CBD) (n = 10), 258 benzodiazepines (e.g., clonazepam, alprazolam) (n = 10), antidepressants (e.g., clonipramine, 259 amitriptyline, duloxetine) (n = 9), non-steroidal anti-inflammatory drugs (NSAIDS; e.g., 260 ibuprofen, naproxen) (n = 8), muscle relaxants (e.g., baclofen, cyclobenzaprine) (n = 6), 261 anticonvulsants (e.g., gabapentin, pregabalin, carbamazepine) (n = 6), nerve blockers (e.g., 262 lidocaine, ambroxol) (n = 4), oxycodone (n = 1), and Botox injections (n = 1). Of the respondents 263 who selected "Other", two reported using Tylenol, one reported Tramadol (opioid), one reported 264 flunarizine, and one reported valacyclovir.

265 The perceived effectiveness of these pharmaceutical interventions varied (Figure 6). Out 266 of the 63 effectiveness ratings provided across all pharmaceutical interventions, 55.56% (n = 35) 267 of the ratings indicated that the treatment had no effect on pain hyperacusis (0% pain relief) and 268 3.17% (n = 2) indicated that the treatment made their pain hyperacusis worse (3.17%, n = 2). Some patients reported modest-to-excellent effects (75-100% pain relief) from benzodiazepenes 269 270 (n = 3), nerve blockers (n = 2), anticonvulsants (n = 2), Tylenol (n = 1), oxycodone (n = 1), and 271 Botox (n = 1). The one participant who tried Botox reported that the excellent effect (100% pain 272 relief) was experienced after injection into the tensor veli palatini muscle. That participant 273 previously received Botox injections in the masseter, occipital muscles, and temporal muscles 274 with limited effect. Two other participants reported that they are currently seeking off-label

Botox injections for pain hyperacusis. Cannabinoids were consistently rated as ineffective for pain relief (n = 9), with one participant indicating that they made their pain hyperacusis worse.

277 Use and perceived effectiveness of non-pharmaceutical interventions were also highly 278 variable (Figure 6). Respondents who tried non-pharmaceutical interventions reported the 279 following treatments, in descending order of frequency: meditation, yoga, or mindfulness therapy 280 (n = 12), counseling (n = 11), cognitive behavioral therapy (n = 9), sound therapy (n = 8), and 281 tinnitus retraining therapy (n = 5). The respondents who selected "Other" reported round and 282 oval window reinforcement surgery (n = 1), low-level laser therapy (n = 1), pranic healing and 283 energy healing (n = 1), TMJ-specific splints or physical therapy (n = 3), chiropractic or massage 284 therapy (n = 2), dry needling and acupuncture (n = 1), and prayer (n = 1). It was noted that nine 285 participants self-administered at least one of these non-pharmaceutical treatments instead of 286 following a prescriptive protocol administered by a professional.

287 Non-pharmaceutical interventions were largely ineffective at providing pain relief in our 288 cohort. Out of the 57 efficacy ratings provided across all non-pharmaceutical interventions, most 289 indicated that these treatments had no effect on pain hyperacusis (0% pain relief) (66.67%, n =290 38) or that these interventions made their noxacusis worse (10.53%, n = 6). All six participants 291 who experienced a worsening of their noxacusis indicated that this occurred after therapies that 292 involved a sound exposure component (i.e., sound therapy or tinnitus retraining therapy). Only a 293 few patients reported modest-to-excellent effects (>75% pain relief) of cognitive behavioral 294 therapy (n = 1), sound therapy (n = 2), TMJ-specific treatments (n = 2), and chiropractic or 295 massage therapy (n = 1).

296

297

299 DISCUSSION

300 Physical Characteristics of Sound-Induced Pain

301 We interviewed adults with severe pain hyperacusis about their experiences, and used 302 their responses to generate follow-up surveys that targeted the primary features of sound-induced 303 pain, other pertinent symptoms, and possible interventions. This study differs from previous 304 work [21] in that we focused solely on individuals with severe pain hyperacusis, allowed them to 305 self-describe the symptoms and experiences that are most important to their quality of life, and 306 collected detailed information about interventions and perceived effectiveness. Identifying the 307 type of pain associated with pain hyperacusis is crucial for appropriate pain management, since 308 the therapeutic approaches can vary drastically. Most participants reported physical sensations 309 consistent with neuropathic pain (i.e., burning, stabbing, throbbing, pinching) that can be 310 accompanied by irritation or inflammation of the nerve near the pain site. The pain often 311 fluctuates in severity, location, and quality, and it can occur immediately after a sound exposure, 312 or it can be delayed by several hours. Even though hyperacusis is generally thought to be an ear 313 disorder and many participants had co-morbid otologic symptoms (e.g., tinnitus, aural fullness), 314 they often reported referred pain (i.e. pain that is not restricted to the ear) and non-otologic 315 sensory sensitivities (e.g., light, touch). Many of these symptoms are consistent with a recent 316 report that surveyed individuals with pain hyperacusis and loudness hyperacusis [21].

Most of our participants attributed the onset of their pain hyperacusis to high-intensity noise exposure or ototoxic substances (**Table 2**). Rodent models demonstrate that acoustic overexposure and ototoxicity facilitate a paradoxical increase in sound-evoked and spontaneous neural activity in the central auditory system [1]. This enhanced central gain following sensory loss is believed to underlie the generation of hyperacusis and tinnitus. While basic science work

322 shows abnormally elevated central auditory gain following acoustic injury, there is little-to-no 323 empirical evidence to support central gain as the underlying cause of pain hyperacusis per se. 324 The behaviors evaluated in rodent models may be interpreted as correlates of elevated loudness 325 perception or hyper-reactivity, but it is unclear whether those rodents experience sound-induced 326 pain. It should also be noted that a large body of literature supports a gradual increase in central 327 auditory gain with advancing age [13], yet older adults do not typically develop sound-induced 328 pain as part of the normal aging process. In the present study, most participants reported low 329 efficacy of interventions that are designed to counteract maladaptive gain in the CNS (e.g., sound 330 therapy, tinnitus retraining therapy, benzodiazepines) and seven participants reported that those 331 therapies made their noxacusis worse.

332 The most pertinent symptoms that our patients report (e.g., neuropathic pain, 333 inflammation, irritation, referred pain, and other otologic symptoms) suggest that the origin of 334 pain hyperacusis may be peripherally mediated as suggested by middle and inner ear models 335 (Figure 1). Approximately 95% of the auditory nerve is comprised of myelinated Type-I neurons 336 that carry acoustic information from the inner hair cells (IHCs) to the cochlear nucleus in the 337 brainstem. The remaining 5% of auditory nerve fibers are unmyelinated Type-II neurons that 338 contact outer hair cells (OHCs). Previous work suggests that Type-II afferents may be involved 339 in auditory nociception, as these fibers have similar morphologic and neurochemical properties 340 to pain-sensing C fibers in the somatic nervous system [4,10,23]. Specifically, both types of 341 fibers can be activated by adenosine triphosphate (ATP), a pain-signaling molecule that is 342 released by damaged tissue, including the OHCs [4,10,23].

Although it is possible that Type-II cochlear afferents could signal tissue damage within
 the cochlea, damage-evoked activity in these neurons has yet to be linked to perceptual outcomes

and it is unclear how this mechanism alone would account for the referred pain and non-pain
 sensations (e.g., aural fullness, pressure, fluttering, muscle spasms) that our participants report.

347 Instead, it has been hypothesized that overload or damage to the tensor tympani muscle (TTM) in 348 the middle ear can lead to pain that spreads via inflammatory processes to activate the trigeminal 349 nerve and generate symptoms consistent with neuropathic pain and other otologic symptoms 350 [12]. The trigeminal nerve transmits sensory information from the middle ear to the 351 trigeminocervical complex (TCC) in the brainstem and then to the cortex. The TCC integrates a 352 variety of sensory and nociceptive inputs from the middle ear, head, and neck regions, providing 353 a possible explanation for the referred pain and head sensations described by many of our 354 participants. Moreover, loud noises can trigger painful episodes in individuals with trigeminal 355 neuralgia suggesting that the auditory and trigeminal pathways share anatomy [11]. These 356 symptoms are also consistent with the related tonic tensor tympani syndrome, wherein TTM 357 myoclonus triggers pain within and around the ear and other otologic symptoms by irritating the 358 trigeminal nerve, increasing tympanic membrane tension, or altering middle ear ventilation [20]. 359 Chronic, painful irritation of the trigeminal nerve can lead to central pain sensitization, possibly 360 accounting for elevated CNS gain in individuals with pain hyperacusis, if such a phenomenon 361 exists.

Notably, two participants in the present study reported that nerve blockers (e.g., lidocaine, ambroxol) had an excellent effect (>90% pain relief) on their noxacusis, and ambroxol has extensive evidence supporting its use in treating neuropathic pain in conditions such as trigeminal neuralgia, fibromyalgia, and complex regional pain syndrome [16]. Another participant indicated that Botox injections in the tensor veli palatini muscle had an excellent effect (>90% pain relief). The tensor veli palatini is innervated by the trigeminal motor root and

may form a functional unit with the TTM to control middle ear pressure [9]. Taken together with existing theories [1,4,10,12,20,23] and other surveys of pain hyperacusis [21], we feel that our results are most consistent with trigeminal nerve involvement. This hypothesis can be clinically tested in the future using locally administered analgesics such as over-the-counter 4% lidocaine ear drops, a common treatment for pain due to acute otitis media in young children [14].

373

374 Emotional and Psychosocial Consequences of Severe Sound-Induced Pain

375 While the psychosocial consequences of hyperacusis are often acknowledged in the 376 literature [8], few studies have focused on the unique considerations of pain hyperacusis [21], 377 and none have invited participants to self-report the areas of greatest concern and impact. Most 378 striking psychosocial consequences reported in this study were the perceived lack of support and 379 empathy from others, persistent social isolation, and reduced physical activity (**Table 2**). All 380 participants reported that people within their social support network do not understand their 381 condition. Of particular concern was that all but one participant indicated that medical and 382 healthcare professionals do not understand their condition. In fact, the three participants that 383 have not tried any interventions for pain relief wrote that they do not trust healthcare 384 professionals to help manage their pain. This is consistent with a recent study that demonstrated 385 inconsistent clinical practices and insufficient education regarding hyperacusis amongst 386 audiologists [7]. In desperation for support and medical advice, many individuals with pain 387 hyperacusis seek counsel on social media. Avoiding healthcare professionals and seeking counsel 388 from non-medical sources complicates the ability to take a structured approach to treatment.

389 The present study shows that individuals with pain hyperacusis try many different types 390 of pharmaceutical and non-pharmaceutical interventions that are often self-prescribed. This

391 unstructured treatment approach makes it difficult to identify the treatments and doses that 392 provide pain relief. With the current approach, it becomes challenging to disentangle the myriad 393 factors that may contribute to the efficacy of a specific treatment. Off-label treatment under 394 professional guidance may help to not only relieve pain for individual sufferers, but to generate 395 consistent protocols and clinical datasets that can be leveraged to study and predict treatment 396 success.

- 397
- 398 Limitations and Future Directions

399 There is a critical need for improved education and interdisciplinary approaches to 400 clinical care and research regarding pain hyperacusis. Healthcare professionals should consider 401 appropriate interventions to improve quality of life by managing the numerous physical, social, 402 and emotional burdens associated with pain hyperacusis. Ear specialists need to collaborate with 403 behavioral health and pain management to develop individualized care plans for patients. As is 404 evident from this report, a holistic treatment plan that not only targets the source of the pain 405 itself, but also serves to mitigate mental and physical health consequences in this population is 406 required. Further development of clinically relevant animal models of pain hyperacusis will be critical for advancing our understanding of its pathophysiological mechanisms and for 407 408 facilitating drug development.

By design, our participants encompassed a small group of individuals with relatively severe pain hyperacusis, and future work will survey a broader and more diverse subset of individuals who experience sound-induced pain. The wide variety of treatments used by our participants precludes systematic analyses of the interrelationships between individual healthrelated variables, symptom severity, and treatment outcomes. Moreover, we cannot quantify the

414	exact dosages, timing, or duration of treatment administration. Despite these limitations, this
415	work allowed participants to self-generate the most pertinent features of pain hyperacusis that
416	have the greatest impact on their quality of life, and which should serve as primary treatment
417	endpoints in future studies.

418

419

420 ACKNOWLEDGMENTS

421 This work was supported by the National Institutes of Health National Institute on Deafness and 422 Other Communication Disorders (NIH NIDCD) K01 DC019647 (PI: Jahn). KNJ reports 423 additional support from the Department of Defense Congressionally Directed Medical Research 424 Program and the American Speech-Language-Hearing Foundation. STK reports support from the American Speech-Language-Hearing Association and the Susan and Jim Jerger Research in 425 426 Audiology Fellowship. MSY reports support from the NIH National Institute of Diabetes and 427 Digestive and Kidney Diseases (NIH NIDDK) R01 DK134893 (PI: Yousuf). KNJ is a member of 428 the Scientific Advisory Board for Hyperacusis Research Ltd. and serves as the scientific advisor 429 for Hyperacusis Central. The authors declare no other conflicts of interests. We thank Marianne 430 Awad for assisting with data collection, our Hyperacusis Patient Advisory Board for insightful 431 discussions, and the participants who generously offered their time to contribute to this work.

432

433 Data Availability Statement: The conducted research was not preregistered in an independent,
434 institutional registry. Data and analysis code are available from the corresponding author upon
435 reasonable request and completion of an institutional data transfer agreement.

436 REFERENCES

- 437 [1] Auerbach BD, Rodrigues PV, Salvi RJ. Central Gain Control in Tinnitus and Hyperacusis.
 438 Frontiers in Neurology 2014;5. doi:10.3389/fneur.2014.00206.
- 439 [2] Baguley DM, Hoare DJ. Hyperacusis: major research questions. Hno 2018;66:358–363.
- 440 [3] Burke JG, O'Campo P, Peak GL, Gielen AC, McDonnell KA, Trochim WMK. An
 441 introduction to concept mapping as a participatory public health research method.
 442 Qualitative Health Research 2005;15:1392–1410.
- [4] Flores EN, Duggan A, Madathany T, Hogan AK, Márquez FG, Kumar G, Seal RP, Edwards
 RH, Liberman MC, García-Añoveros J. A non-canonical pathway from cochlea to brain
 signals tissue-damaging noise. Current Biology 2015;25:606–612.
- 446 [5] Jackson KM, Trochim WMK. Concept Mapping as an Alternative Approach for the
 447 Analysis of Open-Ended Survey Responses. Organizational Research Methods 2002;5:307–
 448 336.
- Jahn KN. Clinical and investigational tools for monitoring noise-induced hyperacusis. The
 Journal of the Acoustical Society of America 2022;152:553–566.
- [7] Jahn KN, Koach CE. Hyperacusis Diagnosis and Management in the United States: Clinical
 Audiology Practice Patterns. American Journal of Audiology 2023:950–961.
- 453 [8] Jüris L, Andersson G, Larsen HC, Ekselius L. Psychiatric comorbidity and personality traits
 454 in patients with hyperacusis. International Journal of Audiology 2013;52:230–235.
- Kierner AC, Mayer R, v. Kirschhofer K. Do the tensor tympani and tensor veli palatini
 muscles of man form a functional unit?: A histochemical investigation of their putative
 connections11In cooperation with the Institute of Anatomy 2, University of Vienna, Vienna,
 Austria. Hearing Research 2002;165:48–52.
- 459 [10] Liu C, Glowatzki E, Fuchs PA. Unmyelinated type II afferent neurons report cochlear
 460 damage. Proceedings of the National Academy of Sciences 2015;112:14723–14727.
- 461 [11] Love S, Coakham HB. Trigeminal neuralgia: Pathology and pathogenesis. Brain
 462 2001;124:2347–2360.
- 463 [12] Noreña AJ, Fournier P, Londero A, Ponsot D, Charpentier N. An Integrative Model
 464 Accounting for the Symptom Cluster Triggered After an Acoustic Shock. Trends in Hearing
 465 2018;22. doi:10.1177/2331216518801725.
- 466 [13] Parthasarathy A, Bartlett EL, Kujawa SG. Age-related Changes in Neural Coding of
 467 Envelope Cues: Peripheral Declines and Central Compensation. Neuroscience
 468 2019;407:21–31.

- 469 [14] Prasad S, Ewigman B. Use anesthetic drops to relieve actute otitis media pain. Journal of
 470 Family Practice 2008;57:370–373.
- [15] Rosing SN, Schmidt JH, Wedderkopp N, Baguley DM. Prevalence of tinnitus and
 hyperacusis in children and adolescents: a systematic review. BMJ Open 2016;6:e010596.
- [16] Russo MA, Baron R, Dickenson AH, Kern K-U, Santarelli DM. Ambroxol for neuropathic
 pain: hiding in plain sight? PAIN 2023;164:3.
- [17] Trochim W, Kane M. Concept mapping: An introduction to structured conceptualization in
 health care. International Journal for Quality in Health Care 2005;17:187–191.
- 477 [18] Trochim WMK. An Introduction To Concept Mapping For Planning and Evaluation.
 478 Evaluation and Program Planning 1989;12:1–16.
- 479 [19] Tyler RS, Pienkowski M, Roncancio ER, Jun HJ, Brozoski T, Dauman N, Coelho CB,
 480 Andersson G, Keiner AJ, Cacace AT, Martin N, Moore BCJ. A review of hyperacusis and
 481 future directions: Part I. Definitions and manifestations. American Journal of Audiology
 482 2014;23:402–419.
- 483 [20] Westcott M. Hyperacusis-induced Pain: Understanding and Management of Tonic Tensor
 484 Tympani Syndrome (TTTS) Symptoms. J Pain Relief 2016;05. doi:10.4172/2167485 0846.1000234.
- 486 [21] Williams ZJ, Suzman E, Woynaroski TG. A Phenotypic Comparison of Loudness and Pain
 487 Hyperacusis: Symptoms, Comorbidity, and Associated Features in a Multinational Patient
 488 Registry. American Journal of Audiology 2021;30:1–18.
- 489 [22] Wood MB, Nowak N, Fuchs PA. Damage-evoked signals in cochlear neurons and 490 supporting cells. Front Neurol 2024;15:1361747.
- 491 [23] Wu JS, Vyas P, Glowatzki E, Fuchs PA. Opposing expression gradients of calcitonin-related
 492 polypeptide alpha (Calca/Cgrpα) and tyrosine hydroxylase (Th) in type II afferent neurons
 493 of the mouse cochlea. Journal of Comparative Neurology 2018;526:425–438.

495 FIGURE LEGENDS

496 Figure 1. Schematic depicting three potential noxacusis mechanisms. In each model, 497 hypothesized components mediating noxacusis are highlighted in red. (A) In the middle ear 498 model, nociceptive signaling is mediated by the mandibular branch of the trigeminal nerve. 499 Trigeminal nerve afferents innervate the tensor tympani and the tensor veli palatini muscles, both 500 proximal to the middle ear space. (B) In the inner ear model, Type II-afferent nerve fibers 501 synapse with outer hair cells and transduce nociceptive signals to the central auditory system. (C) 502 In the central auditory system, maladaptive hyperactivity in the brainstem and brain potentially 503 mediate hyperacusis.

504

Figure 2. A) Schematic of pain locations and descriptors reported during the focus group and the percentage of participants who endorsed (B) neuropathic pain and (C) referred pain. Statement numbers are displayed on the y-axis along with a key word or phrase representing the content of the statement. Full statements are listed in Table 2.

509

Figure 3. The percentage of participants who endorsed (A) otologic symptoms and (B) sensory sensitivities other than pain. Statement numbers are displayed on the y-axis along with a key word or phrase representing the content of the statement. Full statements are listed in Table 2.

513

Figure 4 The percentage of participants who endorsed a lack of empathy or support from others.
Statement numbers are displayed on the y-axis along with a key word or phrase representing the
content of the statement. Full statements are listed in Table 2.

517

Figure 5. The percentage of participants who endorsed (A) isolation and reduced physical activity and (B) mental health consequences. Statement numbers are displayed on the y-axis along with a key word or phrase representing the content of the statement. Items with an asterisk were rated on a Likert scale ranging from *Strongly Disagree* to *Strongly Agree*. Full statements are listed in Table 2.

523

524 Figure 6. The percentage of participants who tried pharmaceutical or non-pharmaceutical

525 interventions (left panel), the number of therapies tried (middle panel), and the general perceived

526 effectiveness of each type of intervention (right panel).

1 TABLES

Table 1. Prevalence of self-reported co-morbid conditions. Thirty-one participants responded to the audiovestibular, neurological, and mental health questions. Chronic pain syndromes and other sensory sensitivities were included in the follow-up survey and thus had 24 total

5 respondents.

Condition	Prevalence
Audiovestibular	
Tinnitus	96.77% (<i>n</i> = 30)
Difficulty hearing in noise	38.71% (<i>n</i> = 12)
Imbalance or dizziness	29.03% (<i>n</i> = 9)
Hearing loss	25.81% (<i>n</i> = 8)
Phonophobia	19.35% (<i>n</i> = 6)
Misophonia	16.13% (<i>n</i> = 5)
Chronic otitis media	9.68% ($n = 3$)
Central auditory processing disorder	6.45% (n = 2)
Neurological / Mental Health	
Anxiety	48.39% (<i>n</i> = 15)
Depression	25.81% (n = 8)
Head injury	19.35% (n = 6)
Post-traumatic stress disorder	19.35% (n = 6)
Chronic migraine	19.35% (n = 6)
Attention deficit hyperactivity disorder	9.68% (n = 3)
Autism spectrum disorder	6.45% (n = 2)
William's syndrome	0.00% (n = 0)
Chronic Pain Syndromes	
Temperomandibular joint disorders	29.17% (<i>n</i> = 7)
Trigeminal neuralgia	4.17% (n = 1)
Fibromyalgia	4.17% (<i>n</i> = 1)
Traumatic peripheral nerve injury	4.17% (<i>n</i> = 1)
Complex regional pain syndrome	0.00% (n = 0)
Diabetic or other metabolic neuropathy	0.00% (n = 0)
Autoimmune disorders	0.00% (n = 0)
Other Sensory Sensitivities	
Sight	41.67% (<i>n</i> = 10)
No other sensory sensitivities	37.50% (n = 9)
Touch	16.67% (n = 4)
Smell	16.67% (n = 4)
Taste	4.17% (<i>n</i> = 1)

Table 2. The 17 clusters and the individual statements within each cluster. The average rating and the standard deviation of the ratings for each cluster are in parentheses next to the cluster title. The average rating for each statement and the percentage of participants who endorsed each statement are in parentheses next to each statement. Clusters and statements are ordered from highest to lowest average rating.

Concept	Staten	nents					
Lack of Empathy or	S84	Medical and healthcare professionals do not understand my hyperacusis symptoms. (4.65, 96.15%)					
Support from Others	S86	Family and friends do not understand my hyperacusis symptoms. (3.77, 100%)					
(4.21, 0.62)							
Isolation and Reduced	582	My lifestyle has changed considerably since the onset of my pain hyperacusis (5.00, 100%)					
Physical Activity	S02 S02	I have become isolated due to my hyperacusis (4.77, 100%)					
$(4 \ 03 \ 0 \ 81)$	S72 S34	I feel I must control the environment around me to reduce my hyperacusis symptoms (4.69, 100%)					
(4.03, 0.81)	S56	My sound-related pain handicans me $(4.35, 88.46\%)$					
	S25	I avoid leaving the house due to my hyperacusis (3.92, 96, 15%)					
	S25 S40	I spend time in silence (3.54, 100%)					
	S40 S42	Lavoid exercise or physical activity due to my hyperacusis (3.15, 92.31%)					
	S66	My sound-related pain makes it difficult for me to speak (2.81, 84, 62%)					
	500	Ny sound related pain makes it difficult for the to speak. (2.01, 04.0270)					
Symptom Setbacks	S81	The longer I am exposed to sound, the worse my hyperacusis symptoms become. (4.77, 100%)					
(3.69, 0.89)	S 87	My hyperacusis gradually became worse over time. (4.19, 88.46%)					
	S13	My sensitivity to sound increases after exposure to a loud sound. (3.96, 100%)					
	S57	Each of my hyperacusis setbacks lasts longer than the one before. (2.85, 100%)					
	S77	Setbacks permanently worsen my pain hyperacusis. (2.69, 80.77%)					
Mental Health	S22	I feel trapped by hyperacusis (4.35.96.15%)					
Consequences	S21	I feel grief because of hyperacusis (3.73, 92, 31%)					
(3 64 0 53)	S27	My hyperacusis makes me feel depressed (3 35, 88, 46%)					
	S18	I feel lonely. (3.15, 92.31%)					
Pain Triggers Severity	585	Certain types of sounds (e.g., high nitched low nitched) cause me more pain than others (4.81, 100%)					
and Time Course	S05	My sound-related pain is chronic (4.69, 100%)					
(3 47 0 84)	\$75	Loudness affects my level of pain $(4.42, 96, 15\%)$					
(3.47, 0.04)	S15	Lam sensitive to electronic sounds (3.65.96.15%)					
	S68	My sound-related pain is severe (3.35.96.15%)					
	S69	My sound-related pain is unmanageable (3.19.92.31%)					
	S67	My pain makes it difficult for me to tolerate even quiet sounds, like a keyboard or the hum of a refrigerator					
	(3.15, 92.31%)						
	S65	My pain in response to sound is delayed. (3.00, 80.77%)					
	S64	My pain occurs immediately after a sound. (2.96, 84.61%)					
	S30	My own voice is unbearable to me. (2.46, 84.62%)					
	S62	Wearing in-the-canal hearing protection is painful. (2.42, 88.46%)					
Control and Avoidance	S19	I must plan to avoid exposure to intolerable sounds. (4.58, 100%)					
Behaviors	S01	Hearing protection devices help me. (4.08, 96.15%)					
(3.35, 1.21)	S10	Sounds I can control (e.g., my own music, my own voice) are easier to tolerate than sounds I cannot control (e.g.,					

	ambu	lance, other people laughing, dogs barking). (3.38, 84.62%)
	S09	I wear hearing protection devices. (3.35, 96.15%)
	S32	White noise helps to improve my hyperacusis symptoms. (1.38, 23.08%)
Pain Laterality	S71	My sound-related pain affects both ears. (3.69, 80.77%)
(3.26, 0.71)	S02	My hyperacusis symptoms are worse in one ear than the other. (3.62, 88.46%)
	S60	My sound-related pain is worse on one side than the other. (3.54, 84.62%)
	S72	My sound-related pain affects only one ear. (2.19, 46.15%)
Emotional Reactions to	S38	I become tense when I am exposed to sounds. (3.31, 88.46%)
Sound	S28	My hyperacusis makes me feel anxious. (3.23, 88.46%)
(3.10, 0.16)	S26	I feel overwhelmed by sound. (3.15, 88.46%)
	S08	Sounds exhaust me. (3.12, 76.92%)
	S24	I startle easily. (3.08, 76.92%)
	S41	I am afraid of sound. (2.96, 73.08%)
	S06	I experience negative emotional reactions to sounds (e.g., anger, annoyance, frustration). (2.85, 69.23%)
Symptom Onset	S79	My hyperacusis symptoms began or became worse due to acoustic trauma (noise exposure). (4.35, 88.46%)
(2.95, 1.23)	S88	My pain hyperacusis began as loudness hyperacusis. (3.58, 76.92%)
	S89	My hyperacusis began suddenly. (3.54, 76.92%)
	S83	My hyperacusis symptoms began or became worse due to exposure to an ototoxic drug/chemical. (1.81, 30.77%)
	S 80	My hyperacusis symptoms began or became worse due to a head injury. (1.50, 23.08%)
Neuropathic Pain	S50	I feel pain in or near my ear(s) when exposed to sound. (4.04, 92.31%)
(2.87, 0.79)	S52	My sound-related pain feels like a burning sensation. (3.08, 80.77%)
	S53	My sound-related pain feels like a stabbing sensation. (2.88, 76.92%)
	S70	My sound-related pain is throbbing. (2.38, 73.08%)
	S54	My sound-related pain feels like a pinching sensation. (1.96, 53.85%)
Fluctuating Severity	S33	White noise makes my hyperacusis symptoms worse. (3.69, 84.62%)
(2.78, 0.77)	S59	My pain levels fluctuate. (3.38, 96.15%)
	S58	The type or severity of my sound-related pain fluctuates. (2.85, 88.46%)
	S74	I cannot tell where my sound-related pain is coming from. (2.04, 65.38%)
	S17	My hyperacusis symptoms get worse whenever I have a cold, sinus infection, or allergies. (1.96, 50.00%)

Otologic Symptoms S04 I experience tinnitus (ringing or noises in the ears or head). (4.69, 96.15%)						
[Non-pain]	n-pain] S05 My tinnitus gets worse due to sound (reactive tinnitus). (3.23, 88.46%)					
(2.64, 0.92)	S12	I feel a pulsating sensation in my ear(s). (2.42, 65.38%)				
	S03	I experience fullness or pressure in my ear(s). (2.38, 80.77%)				
	S11	I feel a fluttering sensation in my ear(s). (2.23, 80.77%)				
	S63	I experience muscle spasms due to my hyperacusis. (2.19, 65.38%)				
	S31	I experience 'vibrations' in my ear(s). (2.15, 57.69%)				
	S 14	I perceive sounds as distorted. (1.81, 46.15%)				
Interference with	S39	My hyperacusis makes it difficult to concentrate. (3.08, 92.31%)				
Essential Functions	S 90	My hyperacusis has made me lose my appetite. (2.31, 50.00%)				
(2.47, 0.54)	S43	My hyperacusis interferes with my sleep. (2.04, 73.08%)				
Other Sensory	S23	I experience more than one type of hyperacusis (e.g., pain + loudness/fear/annoyance). (2.96, 69.23%)				
Sensitivities	S76	My sound-related pain causes fatigue. (2.85, 80.77%)				
(2.34, 0.50)	S07	I cannot tell where sounds are coming from. (2.08, 61.54%)				
	S29	My hyperacusis disorients me. (2.08, 61.54%)				
	S20	I experience other sensory sensitivities (e.g., light, touch, smell, taste). (1.88, 53.85%)				
Irritation/Inflammation	S 61	I experience inflammation at or near the site of my sound-related pain. (2.46, 61.54%)				
(2.08, 0.57)	S16	My ears itch. (2.35, 73.08%)				
	S 78	I can see redness at or near the site of my sound-related pain. (1.42, 30.77%)				
Referred Pain	S44	I feel pain in my face when exposed to sound. (2.08, 73.08%)				
(1.78, 0.21)	S49	I feel pain in the side of my head when exposed to sound. (2.04, 57.69%)				
	S55	My sound-related pain changes locations. (1.81, 65.38%)				
	S51	I feel pain elsewhere in my body when exposed to sound. (1.81, 46.15%)				
	S48	I feel pain in the back of my head when exposed to sound. (1.77, 42.31%)				
	S46	I feel pain in my throat when exposed to sound. (1.65, 34.62%)				
	S45	I feel pain in my neck when exposed to sound. (1.62, 53.85%)				
	S47	I feel pain in the front of my head when exposed to sound. (1.46, 30.77%)				

Table 3. The number of participants (N) who have tried each pharmaceutical and non-pharmaceutical intervention for pain

hyperacusis, along with each intervention's perceived effectiveness.

		Excellent effect (>90% pain	Modest effect (75% pain	Somewhat effective (50%	No effect (0% pain	Made my noxacusis
Intervention	N	relief)	relief)	pain relief)	relief)	worse
Opioid Medications	2					
Oxycodone (including OxyContin)	1	1	0	0	0	0
Other: Tramadol	1	0	0	1	0	0
Non-Opioid Medications	17					
Benzodiazepenes (e.g., clonazepam, alprazolam) Antidepressants (e.g., clomipramine	10	1	2	2	4	1
amitriptyline. duloxetine)	9	0	0	2	7	0
NSAIDS (e.g., ibuprofen, naproxen)	8	0	0	5	3	0
Muscle relaxants (e.g., baclofen,						
cyclobenzaprine)	6	0	0	2	7	0
Anticonvulsants (e.g., gabapentin, pregabalin,						
carbamazepine)	6	1	1	2	2	0
Nerve blockers (e.g., lidocaine, ambroxol)	4	2	0	0	2	0
Botox*	1	1	0	0	0	0
Other: Tylenol	2	0	1	1	0	0
Other: Flunarizine	1	0	0	0	1	0
Other: Valacyclovir	1	0	0	1	0	0
Cannabinoids (marijuana, THC, and/or CBD)	10	0	0	0	9	1
Non-pharmaceutical Interventions	20					
Meditation, yoga, or mindfulness therapy	12	0	0	1	11	0
Counseling	11	0	0	1	10	0
Cognitive behavioral therapy	9	1	0	1	7	0
Sound therapy	8	1	1	0	2	4
Tinnitus retraining therapy	5	0	0	0	3	2
Other: Round and oval window reinforcement	1	0	0	0	1	0
Other: Prism lens therapy	1	0	0	1	0	0

Other: Low level laser therapy	1	0	0	1	0	0
Other: Pranic or Energy Healing	1	0	0	1	0	0
Other: TMJ splint therapy	1	1	0	0	0	0
Other: TMJ physical therapy	2	1	0	0	1	0
Other: Chiropractor or massage therapy	2	0	1	1	0	0
Other: Dry needling	1	0	0	0	1	0
Other: Acupuncture	1	0	0	0	1	0
Other: Prayer	1	0	0	0	1	0

NSAIDS: Non-steroidal anti-inflammatory drugs *Botox was injected into tensor veli palatini muscle.





Sometimes 📃 Ab

About Half the Time 📕 Most of the Time 📕 Always



Sometimes

About Half the Time









